WuXi AppTec IPO tops $353m

By Melissa Fassbender contact

- Last updated on GMT

(Image: WuXi AppTec Co., Ltd.)
(Image: WuXi AppTec Co., Ltd.)
The Chinese contract research and development company WuXi AppTec has raised more than $353m in its initial public offering of common stock on the Shanghai Stock Exchange.

WuXi AppTec's​ initial public offering (IPO) of 104,198,600 shares of common stock was offered on the Shanghai Stock Exchange​ at RMB21.60 per share.

This, equivalent to US$3.39 per share, means the IPO has brought in more than $353m.

According to the company, the funds will be used to build and expand its R&D facilities in China, “further strengthening its capabilities and capacities to better serve global customers and partners.”

The Shanghai-headquartered CDMO operates 26 sites globally and branch offices in China, the US, Germany, UK, Japan, Korea, and Israel. 

Dr. Ge Li, chairman and CEO of WuXi AppTec, said in a statement: "I'm deeply grateful for the great confidence and support we have received from the investment community… It allows us to further focus on our mission and accelerate growth of our enabling platform.”

WuXi AppTec has not responded to a request for comment as of publication.

Related news

Show more

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Related suppliers

Follow us

Products

View more

Webinars